Patent · US Active

Compounds

US10526286B2 · kind B2 · utility

2Cited by

1References

22Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Frank Narjes · Ariccia, IT
Roine Ingemar Olsson · Mölndal, SE
Stefan Von Berg · Mölndal, SE
Sarah Lever · Mölndal, SE

Key dates

Filing date	Jun 4, 2018
Grant date	Jan 7, 2020
Priority date	—
Expiry date	Jun 4, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D407/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present specification provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; a process for preparing such a compound; and to the use of such a compound in the treatment of an RORγ and/or RORγt mediated disease state.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.